Business Context and Reporting Period
Company: James Hardie Industries plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Fiscal Year ended March 31, 2018
Filing Date: May 23, 2018
This filing serves as a cover document referencing the Company's Fiscal Year 2018 results, Annual Review, and Irish Statutory Accounts. The registrant is an Irish-domiciled company with principal executive offices in Dublin.
Key Financial Metrics
The provided text is a cover filing and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced exhibits (Exhibit 99.1, 99.3, and 99.4) which are not included in the input text.
Material Changes
The filing text does not provide specific details on material changes versus the prior comparable period. It references the integration of Fermacell into the business as a risk factor and operational consideration.
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes extensive disclosures regarding forward-looking statements covering future performance, capital expenditure, credit facilities, dividends, and tax structures.
Key Risks and Contingencies:
- Asbestos Liability: Significant exposure related to prior manufacture of asbestos-containing products, including contributions to the Asbestos Injuries Compensation Fund (AICF) and potential shortfalls.
- Legal Proceedings: Exposure to product liability, environmental, and consumer class action lawsuits.
- Market Conditions: Dependence on US and Asia Pacific housing markets, new home construction levels, and consumer confidence.
- Operational Risks: Integration of Fermacell, supply chain costs, and currency exchange rate fluctuations.
- Regulatory: Compliance with tax laws, environmental regulations, and health and safety laws.
Investor Verification Checklist
- Review Exhibit 99.1 (Fiscal Year 2018 Company Announcement) for actual revenue and earnings figures.
- Examine Exhibit 99.4 (Irish Statutory Accounts) for audited financial statements and debt covenants.
- Verify the status and funding adequacy of the Asbestos Injuries Compensation Fund (AICF).
- Assess the progress and financial impact of the Fermacell integration.
- Monitor currency exchange rates given the company's international operations and reporting currency.